This article reports a case of suspected drug-induced kidney injury in a chronic disease patient during hospital treatment. Clinical pharmacists reviewed relevant literature and evaluated and analyzed it, considering it to be related to the improper use of valaciclovir. According to the advice of the clinical pharmacist, the dosage of valaciclovir was adjusted according to the patient's real-time creatinine clearance rate, and treatment measures such as fluid replacement and diuresis were given. The patient's renal function and other indicators decreased. After 6 weeks of discharge, outpatient follow-up showed stable renal function indicators. It reminds the medical staff when valaciclovir is used in patients with chronic kidney disease, it is necessary to closely monitor changes in renal function, and adjust the dosage timely, supplement appropriate fluids during medication, and ensure sufficient urine volume to avoid acute kidney damage caused by drug crystallization deposition in the renal tubules.
1.盛丽英, 王丽英, 裘银久. 谈临床合理用药[J]. 中国医药导报, 2007, 4(28): 154. [Sheng LY, Wang LY, Qiu YJ. On rational use of drugs in clinical practice[J] China Medical Journal, 2007, 4(28): 154.] DOI: 10.3969/j.issn.1673-7210.2007.28.114.
2.杨萍. 用药不当的几大因素[J]. 中国医药导报, 2006, 3(26): 141-142. [Yang P. Several major factors of improper medication[J]. China Medical Journal, 2006, 3(26): 141-142.] DOI: 10.3969/j.issn.1673-7210.2006.26.107.
3.王海燕, 主译. KDIGO急性肾损伤临床实践指南[M].北京: 人民卫生出版社, 2013: 20-21.
4.Sanford JP, 著, 范洪伟, 主译. 桑福德抗微生物治疗指南:新译第48版[M]. 北京: 中国协和医科大学出版社, 2019: 236.
5.Elinder CG, Bárány P, Heimbürger O. The use of estimated glomerular filtration rate for dose adjustment of medications in the elderly[J]. Drugs Aging, 2014, 31(7): 493-499. DOI: 10.1007/s40266-014-0187-z .
6.Zhang Y, Cong Y, Teng Y. Acute renal injury induced by valacyclovir hydrochloride: a case report[J]. Exp Ther Med, 2016, 12(6): 4025-4028. DOI: 10.3892/etm.2016.3905.
7.Sagawa N, Tsurutani Y, Nomura K, et al. Acyclovir-induced neurotoxicity and acute kidney injury in an elderly diabetic patient treated with valacyclovir: report of a case[J]. Nippon Ronen Igakkai Zasshi, 2014, 51(6): 581-585. DOI: 10.3143/geriatrics.51.581.
8.Inaba I, Kondo Y, Iwasaki S, et al. Risk evaluation for acute kidney injury induced by the concomitant use of valacyclovir, analgesics, and renin- angiotensin system inhibitors: the detection of signals of drug-drug interactions[J]. Front Pharmacol, 2019, 10: 874. DOI: 10.3389/fphar.2019.00874
9.陈宏, 赖永旭. 盐酸伐昔洛韦的临床研究综述[J].四川医学, 2005, 26(4): 467-468. [Chen H, Lai YX. Review of clinical research on valaciclovir hydrochloride[J]. Sichuan Medical Science, 2005, 26(4): 467-468.] DOI: 10.16252/j.cnki.issn1004-0501-2005.04.076.
10.龚时薇, 龚佑群, 胡琪. 嘌呤核苷类抗病毒药物470例不良反应分析[J].中国药师, 2005, 8(10): 875-877.[Gong SW, Gong YQ, Hu Q. Analysis of 470 cases of adverse reactions of purine nucleoside antiviraldrugs[J].China Pharmacists, 2005, 8(10): 875-877.] DOI: 10.3969/j.issn.1008-049X.2005.10.041.
11.中国药典临床用药须知2020年版[S]. 2020: 1103.
12.方世平, 查仲玲. 药源性肾病[J]. 药物流行病学杂志, 2002, 11(6): 326-330. [Fang SP, Zha ZL. Drug induced nephropathy[J]. Chinese Journal of Pharmacoepidemiology,
2002, 11(6): 326-330.] DOI: 10.3969/j.issn.1005-0698. 2002.06.016.
13.晏琼, 黄秋明, 胡红艳. 5517例药源性肾损害中文文献分析[J]. 中国医药导报, 2009, 6(25): 114-116.[Yan Q, Huang QM, Hu HY. Chinese literature analysis of 5517 cases of drug-induced renal damage[J]. China Medical Herald, 2009, 6(25): 114-116.] DOI: 10.3969/j.issn.1673-7210.2009.25.069.
14.吕礼安, 段贵生, 冯敬芳. 阿昔洛韦致肾损害26例临床分析[J]. 临床肾脏病杂志, 2007, 7(2): 73. [Lyu LA, Duan GS, Feng JF. Clinical analysis of 26 cases of renal damage caused by acyclovir[J]. Miscellaneous Records of Clinical Kidney Diseases, 2007, 7(2): 73.] https://d.wanfangdata.com.cn/periodical/lcszbzz200702012.
15.国家药品监督管理局. 警惕阿昔洛韦导致急性肾功能损害[EB/OL]. (2009-01-12) [2022-03-01]. https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20090112115401567.html.
16.李钗, 梁璐, 李德天, 等. 阿昔洛韦致急性肾损伤的临床分析[J]. 实用药物与临床, 2018, 21(6): 702-705. [Li C, Liang L, Li DT, et al. Clinical analysis of acyclovir induced acute kidney injury[J]. Journal of Practical Medicine and Clinic, 2018, 21(6): 702-705.] DOI: 10.14053/j.cnki.ppcr.201806024.